-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The study, published today in The New England Journal of Medicine, found that compared with standard therapies, dolutegravire-based treatment options have been widely used in adults, reducing 3-18 years of age The chance of treatment failure in young people is about 40%
These findings are based on a randomized controlled trial called ODYSSEY, which involved more than 700 children from 29 clinical centers in Africa, Europe and Asia.
This trial is sponsored by the Penta Foundation and funded by ViiV Healthcare.
Professor Diana Gibb (University College London MRC Clinical Trial Group) is one of the senior authors of this paper.
"Because of the need for separate formulations and research, pediatric medical care often lags far behind adults
Dr.
The lead author of the study, Dr.
"Dolutegravire is a small tablet that is usually taken once a day.
In this study, researchers found that 14% of children treated with dolutegravire experienced treatment failure within two years, compared with 22% of children receiving standard treatment
Evidence from adults suggests that dolutegravir has a high genetic barrier to resistance, which means that over time, the virus is unlikely to develop resistance to it
Past studies have shown that dolutegravire may be related to weight gain in adults, but the researchers said that the new research results are reliable for children.
In the main experiment, all children weighed more than 14 kg, and most of them were over 6 years old
Participants in the trial came from Uganda, Zimbabwe, South Africa, Thailand, the United Kingdom, Spain, Portugal and Germany
Early findings from the ODYSSEY trial showed that children weighing 20 kg or more can safely take adult doses of dolutegravire.
Dr.
Dolutegravire is an integrase inhibitor—that is, it inhibits HIV by inhibiting integrase, which is an enzyme required for virus replication
.
References: December 29, 2021, " New England Journal of Medicine ", "ODYSSEY: dolutegravire for first-line and second-line treatment of childhood HIV"
.
